Skip to main content

Table 1 Patient characteristics

From: Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma

 

Luminal IDC (n = 1661)

Luminal ILC (n = 104) (n = 104)

 
 

n

%

n

%

P-value

Median follow-up time(months)

53

49.5

 

Age(years)

 Median

53

53

 

  < 50

678

40

44

42

 

50

982

59

60

57

0.768

Menopause status

 Pre

812

48

52

50

 

 Post

844

50

50

48

0.703

Histological grade

 1

486

29

68

65

 

 2

875

52

26

25

 

 3

248

14

2

1

<0.001

Tumor size

 T1

1174

70

57

54

 

 T2

422

25

40

38

 

 T3

63

3

7

6

0.002

ER(Allred score)

 3

19

1

0

0

 

 4

31

2

0

0

 

 5

30

2

1

1

 

 6

62

4

5

5

 

 7

246

15

15

14

 

 8

1273

76

83

80

0.575

HER2 status

 0

439

26

25

24

 

 1

995

60

67

64

 

 2(FISH-)

227

14

12

12

0.682

Lymph node status

 Positive

489

29

34

32

 

 Negative

1021

61

61

58

0.492

Initial surgical treatment

     

 BCS

779

47

41

39

 

 Mastectomy

882

53

63

61

0.007

 Positive margins

38

2.2

7

6.7

0.016

Endocrine therapy

 Yes

1424

85

99

95

 

 No

231

13

5

4

0.008

Chemotherapy

 Yes

672

40

44

42

 

 No

982

59

60

57

0.735

  1. IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, FISH fluorescent in situ hybridization, BCS breast conserving surgery